Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Biodesix (BDSX) EBT Margin (2019 - 2025)

Historic EBT Margin for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to 41.92%.

  • Biodesix's EBT Margin rose 166600.0% to 41.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 49.85%, marking a year-over-year increase of 165800.0%. This contributed to the annual value of 59.95% for FY2024, which is 437000.0% up from last year.
  • Biodesix's EBT Margin amounted to 41.92% in Q3 2025, which was up 166600.0% from 58.03% recorded in Q2 2025.
  • Biodesix's EBT Margin's 5-year high stood at 21.6% during Q1 2021, with a 5-year trough of 238.21% in Q1 2022.
  • Its 5-year average for EBT Margin is 107.16%, with a median of 91.44% in 2024.
  • Per our database at Business Quant, Biodesix's EBT Margin soared by 1722600bps in 2021 and then tumbled by -2166100bps in 2022.
  • Quarter analysis of 5 years shows Biodesix's EBT Margin stood at 182.38% in 2021, then rose by 6bps to 171.13% in 2022, then skyrocketed by 63bps to 62.71% in 2023, then skyrocketed by 34bps to 41.12% in 2024, then dropped by -2bps to 41.92% in 2025.
  • Its last three reported values are 41.92% in Q3 2025, 58.03% for Q2 2025, and 60.26% during Q1 2025.